Bolt Biotherapeutics (BOLT) Research & Development (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Research & Development of $4.8 million for Q1 2026, down 3.19% sequentially from $5.0 million in Q4 2025, and down 49.23% YoY from $9.5 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Research & Development (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Research & Development for 7 years, with the latest figure at $4.8 million in Q1 2026.
- Quarterly Research & Development fell 49.23% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (down 52.73% YoY) and the FY2025 annual result came in at $28.5 million, down 50.35% from the prior year.
- Research & Development eased to $4.8 million in Q1 2026 per BOLT's latest filing, from $5.0 million in the prior quarter.
- Over five years, Research & Development peaked at $19.0 million in Q3 2022 and troughed at $4.8 million in Q1 2026.
- A 5-year average of $13.3 million and a median of $15.0 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 30.14% in 2022, then sank 57.45% in 2025.
- Over 5 years, Research & Development stood at $16.8 million in 2022, then fell by 3.1% to $16.3 million in 2023, then declined by 28.18% to $11.7 million in 2024, then tumbled by 57.45% to $5.0 million in 2025, then slipped by 3.19% to $4.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $4.8 million, $5.0 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - | 5.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.15 Mn |
| Mar 31, 2026 | 4.83 Mn |
| Dec 31, 2025 | 4.99 Mn |
| Sep 30, 2025 | 6.54 Mn |
| Jun 30, 2025 | 7.50 Mn |
| Mar 31, 2025 | 9.51 Mn |
| Dec 31, 2024 | 11.72 Mn |
| Sep 30, 2024 | 13.79 Mn |
| Jun 30, 2024 | 15.43 Mn |
| Mar 31, 2024 | 16.53 Mn |
| Dec 31, 2023 | 16.32 Mn |
| Sep 30, 2023 | 14.95 Mn |
| Jun 30, 2023 | 15.64 Mn |
| Mar 31, 2023 | 14.63 Mn |
| Dec 31, 2022 | 16.85 Mn |
| Sep 30, 2022 | 18.97 Mn |
| Jun 30, 2022 | 18.92 Mn |
| Mar 31, 2022 | 18.39 Mn |
| Dec 31, 2021 | 22.48 Mn |
| Sep 30, 2021 | 19.34 Mn |